Insulatard Flexpen (Insulin Human)

• Insulatard Flexpen provides basal insulin therapy for diabetes mellitus, helping to regulate blood glucose levels.
• Diabetes mellitus type 1: supplies long‑acting insulin to control fasting glucose and reduce hyperglycemia.
• Diabetes mellitus type 2: adds basal insulin when oral agents are insufficient to achieve glycaemic targets.
• Gestational diabetes: may be used under specialist supervision to maintain maternal glucose control.

• Insulin Human binds to insulin receptors on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production, thereby lowering circulating blood glucose levels.

Insulatard Flexpen may cause a range of adverse reactions. Monitoring and prompt reporting are recommended.

Common Side Effects

• Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase in body weight with chronic use.
• Lipodystrophy: localized changes in fat tissue at injection sites.
• Mild allergic reactions: rash or urticaria.

Serious or Rare Side Effects

• Severe hypoglycaemia: loss of consciousness or seizures requiring immediate medical attention.
• Anaphylactic reaction: rare systemic allergic response with difficulty breathing or swelling.
• Insulin edema: fluid retention causing swelling of extremities.
• Hypokalemia: low potassium levels, especially with high insulin doses.
• Lipohypertrophy: significant fat accumulation leading to erratic insulin absorption.

• When using Insulatard Flexpen, consider the following safety measures.
• Dose adjustment: individualize dosing based on regular glucose monitoring and clinical response.
• Hypoglycaemia risk: educate patients to recognize early signs and have fast‑acting carbohydrates available.
• Renal impairment: assess kidney function and consider lower doses to avoid prolonged insulin action.
• Pregnancy: use only if the expected benefit outweighs potential risk to the fetus.
• Drug interactions: review concomitant medications that may potentiate or diminish insulin effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulatard Flexpen can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Concurrent sulfonylureas or meglitinides: may cause severe hypoglycaemia.
• Beta‑blockers: can mask hypoglycaemia symptoms, delaying recognition.
• Excess alcohol: potentiates insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance insulin sensitivity, requiring dose review.
• Thiazide diuretics: can raise blood glucose, potentially needing higher insulin doses.
• Corticosteroids: increase insulin resistance, possibly necessitating dose escalation.